This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Save the date!
November 6–8, 2023Munich, Germany



Curigin is a team committed to RNA-based gene therapy. We target the disease origins which have been previously known as undruggable. Curigin's R&D has been focused on the development of new therapeutic tools for incurable diseases.

Our bispecific RNAi technology allows us to target two genes at the same time with minimized off-target effects, thus increases therapeutic benefits. As our bispecific RNAi technology can be applied to the most of genes in our genome, currently uncontrollable genes with market drugs such as small molecules or antibodies can be specifically regulated by our bispecific RNAi.

Our bispecific RNAi can be delivered to the system by non-viral and viral methods. Therefore, delivery methods can be determined by characteristics of the disease. For systemic administration, we have developed viral delivery tools that can evade immune surveillance. For the diseases in specific organs such as eyes or liver, our RNAi can directly be administered to the organ via non-viral delivery methods.